Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy
- 29 September 2017
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 474 (20), 3391-3402
- https://doi.org/10.1042/bcj20170583
Abstract
Carbidopa is used with l-DOPA (l-3,4-dihydroxyphenylalanine) to treat Parkinson's disease (PD). PD patients exhibit lower incidence of most cancers including pancreatic cancer, but with the notable exception of melanoma. The decreased cancer incidence is not due to l-DOPA; however, the relevance of Carbidopa to this phenomenon has not been investigated. Here, we tested the hypothesis that Carbidopa, independent of l-DOPA, might elicit an anticancer effect. Carbidopa inhibited pancreatic cancer cell proliferation both in vitro and in vivo. Based on structural similarity with phenylhydrazine, an inhibitor of indoleamine-2,3-dioxygenase-1 (IDO1), we predicted that Carbidopa might also inhibit IDO1, thus providing a molecular basis for its anticancer effect. The inhibitory effect was confirmed using human recombinant IDO1. To demonstrate the inhibition in intact cells, AhR (aryl hydrocarbon receptor) activity was monitored as readout for IDO1-mediated generation of the endogenous AhR agonist kynurenine in pancreatic and liver cancer cells. Surprisingly, Carbidopa did not inhibit but instead potentiated AhR signaling, evident from increased CYP1A1 (cytochrome P450 family 1 subfamily A member 1), CYP1A2, and CYP1B1 expression. In pancreatic and liver cancer cells, Carbidopa promoted AhR nuclear localization. AhR antagonists blocked Carbidopa-dependent activation of AhR signaling. The inhibitory effect on pancreatic cancer cells in vitro and in vivo and the activation of AhR occurred at therapeutic concentrations of Carbidopa. Chromatin immunoprecipitation assay further confirmed that Carbidopa promoted AhR binding to its target gene CYP1A1 leading to its induction. We conclude that Carbidopa is an AhR agonist and suppresses pancreatic cancer. Hence, Carbidopa could potentially be re-purposed to treat pancreatic cancer and possibly other cancers as well.This publication has 42 references indexed in Scilit:
- Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug TargetToxicological Sciences, 2013
- The Aryl Hydrocarbon Receptor Mediates Leflunomide-Induced Growth Inhibition of Melanoma CellsPLOS ONE, 2012
- Activation of the Aryl-Hydrocarbon Receptor Inhibits Invasive and Metastatic Features of Human Breast Cancer Cells and Promotes Breast Cancer Cell DifferentiationMolecular Endocrinology, 2010
- Genes involved with folate uptake and distribution and their association with colorectal cancer riskCancer Causes & Control, 2009
- Cytochrome P450 CYP1A1: wider roles in cancer progression and preventionBMC Cancer, 2009
- Are Parkinson disease patients protected from some but not all cancers?Neurology, 2007
- Indoleamine 2,3-dioxygenase and tumor-induced toleranceJCI Insight, 2007
- Induction of Cyp1a1 Is a Nonspecific Biomarker of Aryl Hydrocarbon Receptor Activation: Results of Large Scale Screening of Pharmaceuticals and Toxicants in Vivo and in VitroMolecular Pharmacology, 2007
- Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literatureMelanoma Research, 2006
- Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancerOncogene, 2002